2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Baxter International company profile · medical products, systems & pharmaceuticals · history · financial snapshot · S&P 500 rank #461 · 百特公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | BAX (NYSE) |
| Company | Baxter International Inc. |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment |
| S&P 500 rank (by weight) | #461 · 0.02% (Nov 3, 2026) |
| Sector rank (by market cap) | #52 in Health Care (Nov 3, 2026) |
| Share price (frozen benchmark) | $25.49 (Nov 3, 2026) |
| Headquarters | Deerfield, Illinois |
| Founded | 1931 |
| CEO | José Almeida (Chair, President and CEO) |
| Employees | Not available |
| Market cap | $13.19B (Nov 3, 2026) |
WHAT IT DOES
Baxter International makes medical products and therapies used in hospitals and homes — infusion pumps and IV solutions, surgical products, renal care and pharmaceuticals — sold through its Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals segments. FY2025 sales were $11,244M, up 5.7% from $10,636M, and gross profit was $3,379M, a 30.1% margin.
The headline is a second consecutive GAAP loss: operating income was a loss of $308M, versus a profit of $14M in 2024, and net income was a loss of $957M, versus a loss of $649M in 2024, with a diluted loss per share of $1.87 versus $1.27. A quotelinks prose claim of EPS $2.27 contradicts its own table and the Zacks, roic and Fidelity tables and is rejected — the table figure of −$1.87 is used. Sales growth alongside a widening loss says charges, restructuring and portfolio costs, not demand, drive the GAAP line.
Portfolio change frames the comparison: the kidney care business (Vantive) was sold in early 2025, so Baxter's FY2025 perimeter is smaller and more hospital-focused than FY2024's. Segment figures for FY2025 were not verified from the sources used, so the segments are listed qualitatively.
BUSINESS SEGMENTS — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Medical Products and Therapies | — | — | — |
| Healthcare Systems and Technologies | — | — | — |
| Pharmaceuticals | — | — | — |
| Total sales | $11,244M | 100% | +5.7% |
HISTORY
| Year | Milestone |
|---|---|
| 1931 | Donald Baxter founds Baxter Laboratories in Glenview, Illinois, making intravenous solutions |
| 1950 | Baxter introduces the first flexible plastic IV container, replacing glass bottles |
| 1971 | Baxter lists publicly, growing into a global hospital supplier |
| 2015 | Baxter spins off Baxalta, its biopharmaceutical business, focusing on medical products |
| 2025 | Baxter sells its kidney care business (Vantive) in early 2025; FY2025 sales reach $11,244M with a net loss of $957M |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Sales | $11,244M (+5.7% YoY) |
| Gross profit | $3,379M (30.1% margin) |
| Operating income (loss) | -$308M (vs +$14M in FY2024) |
| Net income (loss) | -$957M (vs -$649M in FY2024) |
| Diluted loss per share | -$1.87 (vs -$1.27 in FY2024) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Baxter International is the S&P 500's hospital-supply name: at a 0.02% index weight and Health Care #52, it is the index's main exposure to the infusion pumps, IV solutions and surgical products that every hospital runs on.
Its sales-growth-versus-loss split is a standing read on medical-device restructuring — $11,244M of sales growing 5.7% while the GAAP line loses $957M says the story is portfolio cost, not hospital demand.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 close) and Slickcharts S&P 500 analysis page (market cap) |
| Financials | Baxter International FY2025 Form 10-K, filed Feb 12, 2026 (fiscal year ended Dec 31, 2025) |
| Sector classification | GICS (Health Care Equipment) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | BAX(NYSE) |
| 公司 | Baxter International Inc. |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健設備 |
| 標普500排名(按權重) | #461 · 0.02%(2026 年 11 月 3 日) |
| 板塊內排名(按市值) | 醫療保健第 #52(2026 年 11 月 3 日) |
| 股價(凍結基準) | $25.49(2026 年 11 月 3 日) |
| 總部 | 美國伊利諾伊州迪爾菲爾德 |
| 成立 | 1931 年 |
| 行政總裁 | José Almeida(董事長、總裁兼行政總裁) |
| 員工 | Not available |
| 市值 | $13.19B(2026 年 11 月 3 日) |
業務概覽
Baxter International 製造醫院與家庭使用的醫療產品與療法——輸液泵與靜脈輸液、外科產品、腎臟護理與藥品——通過醫療產品與療法、醫療保健系統與技術、藥品三大板塊銷售。FY2025 銷售額為 $11,244M,較 $10,636M 增長 5.7%;毛利為 $3,379M,利潤率 30.1%。
標題是一連第二年的 GAAP 虧損:營業利潤為虧損 $308M,對比 2024 年盈利 $14M;淨利潤為虧損 $957M,對比 2024 年虧損 $649M;攤薄每股虧損為 $1.87,對比 $1.27。quotelinks 正文聲稱每股盈利 $2.27,與其自身表格及 Zacks、roic 與 Fidelity 表格相矛盾,予以拒絕——採用表格數字 −$1.87。銷售增長而虧損擴大,說明撥備、重組與組合成本、而非需求,驅動 GAAP 數字。
組合變化框定比較:腎臟護理業務(Vantive)於 2025 年初出售,故 Baxter 的 FY2025 範圍較 FY2024 更小、更聚焦醫院。FY2025 板塊數字未自所用來源核實,故板塊只作定性列示。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 醫療產品與療法 | — | — | — |
| 醫療保健系統與技術 | — | — | — |
| 藥品 | — | — | — |
| 銷售額合計 | $11,244M | 100% | +5.7% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1931 | Donald Baxter 在伊利諾伊州格倫維尤創立 Baxter Laboratories,生產靜脈輸液 |
| 1950 | Baxter 推出首款柔性塑料靜脈輸液容器,取代玻璃瓶 |
| 1971 | Baxter 公開上市,成長為全球醫院供應商 |
| 2015 | Baxter 分拆 Baxalta 生物製藥業務,聚焦醫療產品 |
| 2025 | Baxter 於 2025 年初出售腎臟護理業務(Vantive);FY2025 銷售額達 $11,244M,淨虧損 $957M |
競爭地位
財務快照 — FY2025
| 銷售額 | $11,244M(同比 +5.7%) |
| 毛利 | $3,379M(利潤率 30.1%) |
| 營業利潤(虧損) | −$308M(FY2024 為 +$14M) |
| 淨利潤(虧損) | −$957M(FY2024 為 −$649M) |
| 攤薄每股虧損 | −$1.87(FY2024 為 −$1.27) |
主要風險
對標普500的重要性
Baxter International 是標普500的醫院供應股:指數權重 0.02%、醫療保健第 #52,是指數對每家醫院都運行的輸液泵、靜脈輸液與外科產品的主要敞口。
其銷售增長與虧損的分裂,是醫療器械重組的常設讀數——$11,244M 銷售額增長 5.7% 而 GAAP 數字虧損 $957M,說明故事是組合成本,而非醫院需求。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日收盤)及 Slickcharts 標普500分析頁(市值) |
| 財務 | Baxter International FY2025 Form 10-K,於 2026 年 2 月 12 日申報(財政年度截至 2025 年 12 月 31 日) |
| 板塊分類 | GICS(醫療保健設備),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 06:17 · updated 2026-11-14 22:59 · rev 5